0001193125-16-770965.txt : 20161117 0001193125-16-770965.hdr.sgml : 20161117 20161117161602 ACCESSION NUMBER: 0001193125-16-770965 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20161114 ITEM INFORMATION: Cost Associated with Exit or Disposal Activities FILED AS OF DATE: 20161117 DATE AS OF CHANGE: 20161117 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ONCOGENEX PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0000949858 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 954343413 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 033-80623 FILM NUMBER: 162005105 BUSINESS ADDRESS: STREET 1: 19820 NORTH CREEK PARKWAY STREET 2: SUITE 201 CITY: BOTHELL STATE: WA ZIP: 98011 BUSINESS PHONE: 425-686-1500 MAIL ADDRESS: STREET 1: 19820 NORTH CREEK PARKWAY STREET 2: SUITE 201 CITY: BOTHELL STATE: WA ZIP: 98011 FORMER COMPANY: FORMER CONFORMED NAME: SONUS PHARMACEUTICALS INC DATE OF NAME CHANGE: 19950825 8-K 1 d293988d8k.htm FORM 8-K Form 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 14, 2016

 

 

ONCOGENEX PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   033-80623   95-4343413

(State or other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

19820 North Creek Parkway

Bothell, Washington

   98011
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s telephone number, including area code: (425) 686-1500

N/A

(Former name or former address if changed since last report.)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

Item  2.05    Costs Associated with Exit or Disposal Activities.

On November 14, 2016, OncoGenex Pharmaceuticals, Inc. (the “Company”) committed to a further reduction in the Company’s workforce in order to preserve the Company’s resources as it determines future strategic plans. The Company will eliminate five positions and estimates that it will incur approximately $750,000 in cash expenditures as a result of the workforce reduction, substantially all of which will be severance costs. The Company expects the workforce reduction to be substantially complete in the fourth quarter of 2016.

 

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

    ONCOGENEX PHARMACEUTICALS, INC.
Date: November 17, 2016     /s/ John Bencich
    John Bencich
    Chief Financial Officer

 

3